Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYT 004 MelQbG10

Drug Profile

CYT 004 MelQbG10

Alternative Names: CYT004-MelQbG10; Melan-A VLP vaccine - Cytos; Melanoma virus-like particle vaccine - Cytos

Latest Information Update: 31 Aug 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytos Biotechnology
  • Class Cancer vaccines; Virus-like particle vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 01 Jul 2010 Cytos Biotechnology completes a phase II trial in Malignant melanoma in Switzerland
  • 24 Feb 2009 Phase II development is ongoing in Switzerland
  • 22 Nov 2007 Interim immunogenicity, adverse event and efficacy data from three phase IIa trials in malignant melanoma released by Cytos Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top